A Randomized, Open-label Trial of Gefitinib Versus Combination of Vinorelbine Plus Platinum as Adjuvant Treatment in Pathological Stage II-IIIA(N1-N2) Non-small Cell Lung Cancer With EGFR (Epidermal Growth Factor Receptor Activating) Mutation
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 08 Jun 2017
At a glance
- Drugs Gefitinib (Primary) ; Cisplatin; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ADJUVANT
- 10 Jun 2017 Biomarkers information updated
- 06 Jun 2017 Trial design of the study presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 28 Feb 2017 Planned End Date changed from 1 Aug 2018 to 1 Dec 2020.